JSM 2015 Preliminary Program

Online Program Home
My Program

Legend: Washington State Convention Center = CC, Sheraton Seattle = S, Grand Hyatt = GH and The Conference Center = TCC
* = applied session       ! = JSM meeting theme

Activity Details
412 * ! Tue, 8/11/2015, 2:00 PM - 3:50 PM CC-610
Practical Issues with the PFS Endpoint in Cancer Clinical Trial — Topic Contributed Papers
Biopharmaceutical Section
Organizer(s): Sudhakar Rao, Janssen R&D
Chair(s): Sudhakar Rao, Janssen R&D
2:05 PM A Model to Analyze Survival in a Clinical Trial Where the Treatment Is Primarily Expected to Delay Disease Progression — Dianne M. Finkelstein, Massachusetts General Hospital/Harvard University ; David A. Schoenfeld, Massachusetts General Hospital/Harvard University
2:25 PM Is the Median PFS Difference Meaningful for Assessing Treatment Effect? — Steven Snapinn, Amgen
2:45 PM An Audit Plan in Oncology Clinical Trials — Steven Sun, Johnson & Johnson
3:05 PM Use of PFS and PFS2 in Cancer Clinical Trials — Tommy Fu, Celgene ; Marie-Laure Bravo, Celgene ; Chengqing Wu, Celgene ; Guang Chen, Celgene ; Zhinuan Yu, Celgene ; Qiang Xu, Celgene
3:25 PM Discussant: Surya Mohanty, Johnson & Johnson
3:45 PM Floor Discussion




For program information, contact the JSM Registration Department or phone (888) 231-3473.

For Professional Development information, contact the Education Department.

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

2015 JSM Online Program Home